查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870514

DNA疫苗市場按應用、技術平台、遞送方式、給藥途徑、研發階段和最終用戶分類－2025年至2032年全球預測

DNA Vaccine Market by Application, Technology Platform, Delivery Method, Administration Route, Development Stage, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，DNA 疫苗市場規模將達到 8.6867 億美元，複合年成長率為 14.09%。

關鍵市場統計數據
基準年 2024 3.0254億美元
預計年份：2025年 3.4445億美元
預測年份 2032 8.6867億美元
複合年成長率 (%) 14.09%

引言概述了正在重塑全球DNA疫苗研發的新科學動能、遞送技術創新和戰略意義。

在核酸療法整體和遞送技術改進的推動下，DNA疫苗的科學和商業性進程已進入嚴格檢驗和選擇性推進階段。儘管DNA疫苗歷來因其理論優勢（熱穩定性、易於設計以及能夠編碼複雜抗原）而備受推崇，但由於遞送效率低和人體免疫抗原性不足，其廣泛應用受到限制。近年來，質體工程、線性及微環DNA平台以及對先天免疫調控機制更深入理解的進步，重新激發了研發人員、資助者和臨床研究人員的興趣。

技術、臨床策略和相關人員行為的變革性變化正在加速DNA疫苗的實際應用和策略合作。

DNA疫苗領域正經歷一場變革，其驅動力主要來自三個相互交織的因素：技術進步、臨床檢驗趨勢以及相關人員不斷變化的期望。分子支架和載體設計的進步拓展了能夠在體內穩定表達的抗原構建體的種類，而線性DNA和微環平台的出現則為研發人員提供了在表達效率和生產便捷性之間進行權衡的新選擇。同時，電穿孔、脂質奈米顆粒和聚合物奈米顆粒等遞送方式的改進顯著降低了傳統上有效活化免疫反應的障礙。

2025年關稅趨勢和貿易政策調整將如何影響供應鏈策略、採購重點和製造地區域化決策

2025年關稅調整和貿易政策調整的累積影響，進一步加劇了支持DNA疫苗研發和生產的全球供應鏈的複雜性。質體和線性DNA生產所需的關鍵原料——包括專用酵素、層析法樹脂、一次性生物製程組件和試劑級耗材——極易受到跨境成本波動的影響。在關稅導致投入成本上升或採購不確定性增加的地區，發起公司和合約研發生產機構（CDMO）正透過重新評估籌資策略、擴大庫存緩衝以及與當地供應商建立合作關係來穩定採購前置作業時間，從而應對這一挑戰。

關鍵細分洞察揭示了應用重點、平台選擇、管理方法、臨床階段和最終用戶趨勢將如何影響專案策略和商業化計劃。

基於細分市場的洞察揭示了不同適應症、技術平台、給藥方式、給藥途徑、研發階段和最終用戶所對應的獨特研發路徑和商業性考慮。在應用領域方面，針對感染疾病（感染疾病為細菌感染、寄生蟲感染和病毒感染疾病）的項目往往優先考慮快速免疫誘導、低溫運輸耐受性和擴充性。同時，專注於骨髓惡性腫瘤和固態腫瘤的腫瘤計畫則優先考慮抗原特異性、合併免疫療法策略和腫瘤微環境調控。平台選擇（線性DNA、微環DNA或質體DNA）會影響生產複雜性、有效載荷能力和基因組安全性認知，進而影響監管互動和合作夥伴選擇。

提供切實可行的區域性見解，闡釋美洲、歐洲、中東和非洲以及亞太地區在監管、製造業和醫療保健體系方面的差異如何影響專案策略。

區域觀點影響著不同市場中開發商和投資者的策略重點，這些市場擁有不同的法規結構、醫療基礎設施和生產能力。在美洲，強大的資本市場和創新型的法規環境促進了早期臨床試驗和公私合營，而集中的製造群支持快速規模化生產和垂直整合的供應鏈。同時，歐洲、中東和非洲地區（EMEA）是一個異質性環境，監管協調工作與多樣化的准入途徑和採購機制並存，迫使申辦方制定靈活的臨床開發計劃和支付方參與策略，以反映當地的報銷實際情況。

關鍵的企業級洞察，闡述了平台創新者、臨床階段生物技術公司、大型製藥合作夥伴和合約研發生產機構 (CDMO) 如何整合自身能力，加速 DNA 疫苗的研發進程。

DNA疫苗領域的企業組成既有競爭又有合作，涵蓋了專業平台開發商、臨床階段生物技術公司、大型製藥合作夥伴以及契約製造組織（CMO）。平台開發商致力於透過分子設計、專有遞送佐劑或生產流程的創新來降低生產成本並提高表達效率，從而實現差異化競爭。臨床階段生物技術公司則傾向於專注於適應症範圍較窄的領域，在這些領域，差異化的免疫學特徵或生物標記組合能夠加速概念驗證。同時，大型製藥企業則傾向尋求策略合作和許可，以完善其現有的疫苗產品組合和分銷能力。

為行業領導者提供實用建議，以優先考慮管理創新、供應鏈韌性、監管策略、合作夥伴關係和客製化商業化方案。

產業領導者可以採取一系列切實有效且影響深遠的舉措，在降低風險的同時，加速產品研發和商業化進程。首先，優先投資於能夠顯著改善抗原表現和提高患者耐受性的遞送技術和給藥途徑，並使這些投資與目標適應症和最終用戶需求相符。其次，透過對多家供應商進行資質認證、探索區域製造夥伴關係以及將關稅和貿易應急預案納入籌資策略，增強供應鏈合格，避免專案中斷，並確保進度按計劃進行。

本研究採用的調查方法結合了文獻綜述、法規審查、專家諮詢和供應鏈分析。

這項高階主管級分析所依據的研究結合了對同儕審查文獻、臨床試驗註冊庫、監管指導文件和已發表技術報告的系統性回顧，並輔以有針對性的專家諮詢。研究對科學和臨床發現進行了三角驗證，以確保臨床前檢驗、給藥方式表現和臨床開發模式的一致性。透過分析近期關稅表、官方貿易公告和供應鏈中斷案例研究，檢驗了貿易和政策影響，重點在於採購和生產決策如何即時調整。

總之，我們將技術進步、營運需求和區域因素綜合起來，共同確定了 DNA 疫苗產生影響的路徑。

總之，DNA疫苗正從一個主要停留在理論層面的可能性轉變為現代免疫療法和預防策略中不可或缺的一部分。平台工程的進步，以及遞送和給藥方法的顯著改進，正在擴大DNA疫苗的適應症範圍，使其更具競爭力。同時，貿易政策趨勢和區域環境的差異等外部因素，要求對生產、採購和打入市場策略進行周密的規劃。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • DNA疫苗奈米顆粒和電穿孔遞送系統的進步提高了臨床試驗中的免疫抗原性。
  • 政府和私人部門加大投資將加速DNA疫苗平台的研究和商業化進程。
  • 開發耐熱質體製劑，以減少全球DNA疫苗分發對低溫運輸的依賴性
  • 利用新型抗原辨識和高通量定序技術開發的個人化癌症DNA疫苗的出現
  • 生技公司與大型製藥公司達成策略性授權協議，加速DNA疫苗研發管線擴張
  • 人類DNA疫苗候選藥物在主要市場獲得監管核准以應對新興感染疾病的里程碑
  • 透過將先進的佐劑系統與質體DNA構建體整合，增強細胞和體液免疫反應。
  • 擴大工業質體生產製程規模，以滿足全球對DNA疫苗臨床試驗日益成長的需求

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 DNA疫苗市場按應用領域分類

  • 感染疾病
    • 細菌感染疾病
    • 寄生蟲感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

9. 按技術平台分類的DNA疫苗市場

  • 線性DNA
  • 迷你環狀DNA
  • 質體DNA

第10章 DNA疫苗市場依遞送方式分類

  • 電穿孔
  • 基因癌症
  • 奈米顆粒遞送
  • 針頭注射

第11章：DNA疫苗市場依給藥途徑分類

  • 皮內給藥
  • 肌肉內注射
  • 鼻腔
  • 皮下注射

第12章 DNA疫苗市場依研發階段分類

  • I期臨床試驗
  • II期臨床試驗
  • III期臨床試驗
  • 商業的
  • 臨床前

第13章 DNA疫苗市場（依最終用戶分類）

  • 診所
  • 醫院
  • 研究所

第14章 DNA疫苗市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 DNA疫苗市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國DNA疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Inovio Pharmaceuticals, Inc.
    • GeneOne Life Science, Inc.
    • VGXI, Inc.
    • Zydus Cadila Ltd.
    • GenScript Biotech Corporation
    • Applied DNA Sciences, Inc.
    • Entos Pharmaceuticals, Inc.
    • Takis Biotech Srl
    • Vical, Inc.
    • Merck & Co., Inc.
Product Code: MRR-1A1A064C0154

The DNA Vaccine Market is projected to grow by USD 868.67 million at a CAGR of 14.09% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 302.54 million
Estimated Year [2025] USD 344.45 million
Forecast Year [2032] USD 868.67 million
CAGR (%) 14.09%

Introduction framing the renewed scientific momentum, delivery innovations, and strategic implications that are reshaping DNA vaccine development globally

The scientific and commercial narrative for DNA vaccines has entered a phase of intensified scrutiny and selective momentum, prompted by broader nucleic acid therapy progress and refined delivery science. Historically, DNA vaccines were celebrated for their theoretical advantages-thermostability, ease of design, and capacity to encode complex antigens-but adoption was constrained by delivery inefficiencies and suboptimal immunogenicity in humans. Recent advances in plasmid engineering, linear and minicircle DNA platforms, and a more nuanced understanding of innate immune modulation have reignited interest among developers, funders, and clinical investigators.

Consequently, technology maturation is converging with pragmatic clinical strategy. Electroporation and nanoparticle-based carriers are demonstrating improved antigen expression and immune priming in trial settings, and intradermal and intramuscular administration routes are being optimized to balance safety with immunologic potency. On the regulatory front, clearer guidance on vector characterization and manufacturing controls is facilitating more predictable development pathways. Taken together, these dynamics are reshaping the risk calculus for both established biologics companies and nimble biotech entrants, creating an environment in which strategic partnerships, targeted investments in delivery technologies, and curated clinical programs are central to realizing the long-promised utility of DNA vaccines.

Transformative shifts in technologies, clinical strategies, and stakeholder behavior that are accelerating DNA vaccine viability and strategic collaboration

The DNA vaccine landscape has experienced transformative shifts driven by three interlocking forces: technological refinement, clinical validation trends, and evolving stakeholder expectations. Advances in molecular scaffolding and vector design have expanded the repertoire of antigen constructs that can be reliably expressed in vivo, and the emergence of linear DNA and minicircle platforms is offering developers alternative trade-offs in expression efficiency and manufacturing simplicity. In parallel, improvements in delivery modalities such as electroporation and lipid- or polymer-based nanoparticles are materially reducing prior barriers to robust immune activation.

Clinical development strategies have also shifted toward combination approaches that pair DNA vaccines with adjuvants, heterologous prime-boost regimens, or checkpoint modulators in oncology. As a result, trial designs are increasingly adaptive and biomarker-driven, with a heavier emphasis on correlates of protection and immune durability. Moreover, the competitive landscape is adapting: long-term players are recalibrating portfolios to incorporate DNA vaccines where they complement existing modalities, while smaller innovators are focusing on niche indications or platform differentiation. These shifts collectively push the field toward pragmatic collaboration, targeted regulatory engagement, and selective capital deployment that prioritize demonstrable clinical value and manufacturable delivery solutions.

How evolving tariff dynamics and trade policy adjustments in 2025 are reshaping supply-chain strategies, procurement priorities, and manufacturing localization decisions

The cumulative impact of tariff changes and trade policy adjustments in 2025 has introduced additional complexity into global supply chains that underpin DNA vaccine development and production. Raw materials critical to plasmid and linear DNA production-specialized enzymes, chromatography resins, single-use bioprocess components, and reagent-grade consumables-are sensitive to cross-border cost fluctuations. Where tariffs have increased input prices or created greater procurement uncertainty, sponsors and contract development and manufacturing organizations have responded by reassessing sourcing strategies, extending inventory buffers, and pursuing localized supplier relationships to stabilize lead times.

These adjustments have practical downstream effects on program timelines and contracting practices. Developers are prioritizing dual-sourcing strategies, qualifying domestic manufacturing partners where feasible, and incorporating tariff contingencies into procurement contracts and milestone planning. Regulatory engagement has become more prominent as companies navigate import documentation, classification disputes, and compliance with evolving trade policies. At the same time, the trade environment has prompted more deliberate capital allocation toward regional manufacturing capabilities and supply-chain resilience initiatives, particularly for entities that view long-term commercial supply as a strategic differentiator rather than a short-term cost issue.

Key segmentation insights illuminating how application focus, platform choice, delivery modality, clinical stage, and end-user dynamics inform program strategy and commercialization planning

Segmentation-driven insights reveal distinct development pathways and commercial considerations across applications, technology platforms, delivery methods, administration routes, development stages, and end users. On the application axis, programs targeting infectious diseases-subdivided into bacterial infections, parasitic diseases, and viral infections-tend to emphasize rapid immune induction, cold-chain resilience, and scalability, while oncology programs focusing on hematological malignancies and solid tumors prioritize antigen specificity, combination immunotherapy strategies, and tumor microenvironment modulation. Platform selection-whether linear DNA, minicircle DNA, or plasmid DNA-shapes manufacturing complexity, payload capacity, and perceptions of genomic safety, influencing both regulatory dialogue and partner selection.

Delivery modalities exert a decisive influence on clinical strategy and patient experience. Electroporation has proven effective for enhancing transfection rates and is commonly paired with intramuscular or intradermal administration to maximize antigen expression, while gene gun approaches and nanoparticle delivery are being optimized to improve tolerability and enable mucosal routes such as intranasal delivery. Needle injection remains a pragmatic option in many clinical settings. Development stage segmentation, which spans preclinical to clinical phases I through III and commercial readiness, dictates different evidence requirements, investment profiles, and partnership models. Finally, the end-user landscape-comprising clinics, hospitals, and research institutions-drives considerations around ease of administration, on-site infrastructure needs, and training requirements, factors that are particularly salient when planning rollouts or pilot implementation studies.

Actionable regional insights that explain how regulatory, manufacturing, and healthcare system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific direct program strategies

Regional perspectives shape strategic priorities for developers and investors across markets with differing regulatory frameworks, healthcare infrastructure, and manufacturing capacity. In the Americas, strong capital markets and an innovation-oriented regulatory environment encourage early-stage trials and public-private partnerships, while concentrated manufacturing clusters support rapid scale-up capabilities and vertically integrated supply chains. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with varied access pathways and procurement mechanisms, prompting sponsors to adopt flexible clinical development plans and payer engagement strategies that reflect local reimbursement realities.

The Asia-Pacific region is characterized by dense manufacturing infrastructure, growing biotech ecosystems, and high-priority public health agendas that favor expedited adoption for vaccines demonstrating clear benefit. These regional attributes influence decisions about clinical trial localization, licensing strategies, and manufacturing siting. As a result, stakeholders are increasingly adopting regionally tailored approaches that align trial designs, regulatory submissions, and market access plans with local norms while preserving global program coherence. Transitioning smoothly across regions requires early cross-jurisdictional regulatory planning and strategic partnerships that can bridge technical, logistical, and policy gaps.

Critical company-level insights describing how platform innovators, clinical biotechs, large pharma partners, and CDMOs are aligning capabilities to accelerate DNA vaccine progress

The competitive and collaborative makeup of companies active in the DNA vaccine space spans specialist platform developers, clinical-stage biotechs, large pharmaceutical partners, and contract manufacturing organizations. Platform developers are differentiating through molecular design, proprietary delivery adjuncts, or manufacturing process innovations intended to reduce cost of goods and improve expression efficiency. Clinical-stage biotechs often focus on narrowly defined indications where a differentiated immunologic profile or compendium of biomarkers can accelerate proof-of-concept, while larger pharmaceutical firms tend to pursue strategic alliances or licensing arrangements to complement existing vaccine portfolios and distribution capabilities.

Contract development and manufacturing organizations play a pivotal role by offering scale, regulatory experience, and process optimization services that de-risk late-stage programs. Academic institutions and translational research centers also contribute through early-stage validation, platform refinement, and investigator-initiated trials. Across these organizational types, successful players balance technical depth with commercial pragmatism, invest in delivery and administration innovations, and cultivate regulatory engagement to smooth path-to-market barriers. Strategic collaborations that bring together complementary capabilities-such as combining a novel platform with an experienced clinical development partner and a CDMO capable of GMP supply-are increasingly the dominant route to de-risked advancement and broader clinical adoption.

Actionable recommendations for industry leaders to prioritize delivery innovation, supply-chain resilience, regulatory strategy, collaborative partnerships, and tailored commercialization playbooks

Industry leaders can adopt a set of pragmatic, high-impact actions to accelerate development and commercial readiness while mitigating risk. First, prioritize investment in delivery technologies and administration pathways that demonstrate reproducible improvements in antigen expression and patient tolerability, aligning these investments with target indication characteristics and end-user needs. Second, strengthen supply-chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff and trade contingencies into procurement strategies to avoid program interruptions and protect timelines.

Third, pursue modular regulatory engagement and adaptive clinical designs that emphasize biomarker-driven endpoints and immune correlates, thereby reducing uncertainty and enabling faster go/no-go decisions. Fourth, cultivate cross-sector collaborations that pair molecular platform expertise with clinical development capability and scalable manufacturing to create end-to-end value chains. Finally, develop tailored commercialization playbooks that reflect regional regulatory norms, reimbursement pathways, and infrastructure constraints, and invest in training and administration support to ensure smooth deployment in clinics and hospitals. Together these actions create a defensible pathway from proof-of-concept through sustainable market access.

Research methodology describing the integrated approach of literature synthesis, regulatory review, expert consultations, and supply-chain analysis that underpins the findings

The research underlying this executive-level analysis combined a structured review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and publicly available technical reports with targeted expert consultations. Scientific and clinical inputs were triangulated to ensure consistency across preclinical validation, delivery modality performance, and clinical development patterns. Trade and policy impacts were assessed through analysis of recent tariff schedules, public trade notices, and supply-chain disruption case studies, with attention to how procurement and manufacturing decisions are adapting in real time.

Qualitative interviews with developers, contract manufacturers, clinical investigators, and regulatory advisors provided context on operational bottlenecks, technology adoption drivers, and preferred partnership archetypes. Throughout the study, findings were cross-checked for technical accuracy and relevance, and conclusions emphasized actionable implications over speculative forecasting. The methodological approach prioritized transparency, reproducibility, and the integration of technical, clinical, and commercial perspectives to produce a synthesis that supports strategic decision-making across stakeholders engaged in the DNA vaccine ecosystem.

Conclusion synthesizing technological progress, operational imperatives, and regional considerations that collectively define the path to DNA vaccine impact

In conclusion, DNA vaccines are transitioning from a primarily theoretical promise to a pragmatic element of contemporary immunotherapy and prophylactic strategies. Advances in platform engineering, coupled with meaningful improvements in delivery methods and administration practices, are expanding the set of indications where DNA vaccines can be competitively positioned. At the same time, external factors such as trade policy dynamics and diverse regional environments require deliberate planning around manufacturing, sourcing, and market-entry strategies.

For stakeholders, success depends on aligning scientific differentiation with operational excellence and regulatory foresight. Those who invest early in delivery optimization, supply-chain resilience, and collaborative partnership models will be positioned to convert technical promise into clinical impact and, ultimately, sustainable adoption. The pathway forward emphasizes targeted, evidence-driven development programs that are regionally informed and operationally pragmatic, enabling DNA vaccines to play a meaningful role in both infectious disease control and oncology care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in nanoparticle and electroporation delivery systems for DNA vaccines improving immunogenicity in clinical trials
  • 5.2. Rising investment from government and private funds fueling accelerated DNA vaccine platform research and commercialization
  • 5.3. Development of thermostable plasmid formulations reducing cold chain dependency for global DNA vaccine distribution
  • 5.4. Emergence of personalized cancer DNA vaccines utilizing neoantigen identification and high throughput sequencing technologies
  • 5.5. Strategic licensing agreements between biotech innovators and major pharma accelerating DNA vaccine pipeline expansions
  • 5.6. Regulatory approval milestones for human DNA vaccine candidates against emerging infectious diseases in key markets
  • 5.7. Integration of advanced adjuvant systems with plasmid DNA constructs enhancing cellular and humoral immune responses
  • 5.8. Scale up of industrial plasmid manufacturing processes to meet growing global demand for DNA vaccine clinical trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Vaccine Market, by Application

  • 8.1. Infectious Diseases
    • 8.1.1. Bacterial Infections
    • 8.1.2. Parasitic Diseases
    • 8.1.3. Viral Infections
  • 8.2. Oncology
    • 8.2.1. Hematological Malignancies
    • 8.2.2. Solid Tumors

9. DNA Vaccine Market, by Technology Platform

  • 9.1. Linear DNA
  • 9.2. Minicircle DNA
  • 9.3. Plasmid DNA

10. DNA Vaccine Market, by Delivery Method

  • 10.1. Electroporation
  • 10.2. Gene Gun
  • 10.3. Nanoparticle Delivery
  • 10.4. Needle Injection

11. DNA Vaccine Market, by Administration Route

  • 11.1. Intradermal
  • 11.2. Intramuscular
  • 11.3. Intranasal
  • 11.4. Subcutaneous

12. DNA Vaccine Market, by Development Stage

  • 12.1. Clinical Phase I
  • 12.2. Clinical Phase II
  • 12.3. Clinical Phase III
  • 12.4. Commercial
  • 12.5. Preclinical

13. DNA Vaccine Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutions

14. DNA Vaccine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. DNA Vaccine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. DNA Vaccine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Inovio Pharmaceuticals, Inc.
    • 17.3.2. GeneOne Life Science, Inc.
    • 17.3.3. VGXI, Inc.
    • 17.3.4. Zydus Cadila Ltd.
    • 17.3.5. GenScript Biotech Corporation
    • 17.3.6. Applied DNA Sciences, Inc.
    • 17.3.7. Entos Pharmaceuticals, Inc.
    • 17.3.8. Takis Biotech S.r.l.
    • 17.3.9. Vical, Inc.
    • 17.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DNA VACCINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DNA VACCINE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DNA VACCINE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DNA VACCINE MARKET SIZE, BY LINEAR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DNA VACCINE MARKET SIZE, BY MINICIRCLE DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DNA VACCINE MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DNA VACCINE MARKET SIZE, BY GENE GUN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DNA VACCINE MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DNA VACCINE MARKET SIZE, BY NEEDLE INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DNA VACCINE MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DNA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DNA VACCINE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DNA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DNA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS DNA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL DNA VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN DNA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN DNA VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. ASEAN DNA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. GCC DNA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. GCC DNA VACCINE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 348. GCC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 349. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 350. GCC DNA VACCINE MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 351. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 352. GCC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 353. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 354. GCC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 355. GCC D